Legend Biotech (LEGN) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Legend Biotech Corp. (LEGN) PT Raised to $86 at RBC Capital
May 14, 2024 6:11 AM EDTRBC Capital analyst Leonid Timashev raised the price target on Legend Biotech Corp. (NASDAQ: LEGN) to $86.00 (from $85.00) while maintaining a Outperform rating.
The analyst comments "This morning LEGN reported 1Q24 earnings and we had a chance to catch up with... More
